Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Hansen

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1986
Disposition of radiolabeled flumequine in rat and dogL I Harrison, D Schuppan, S R Rohlfing, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1984
Determination of flumequine and a hydroxy metabolite in biological fluids by high-pressure liquid chromatographic, fluorometric, and microbiological methodsL I Harrison, D Schuppan, S R Rohlfing, et al.
British Journal of Cancer|October 25, 2017
Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic reviewA Prawira, S F Oosting, T W Chen, et al.
Gynecologic Oncology|July 14, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 studyD M O'Malley, G M Bariani, P A Cassier, et al.
Oral Oncology|May 29, 2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neckD Day, A Prawira, A Spreafico, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyA R Hansen, C Massard, P A Ott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)A Spreafico, A A Heirali, D V Araujo, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumI Stukalin, J C Wells, J Graham, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1986
Disposition of radiolabeled flumequine in rat and dogL I Harrison, D Schuppan, S R Rohlfing, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1984
Determination of flumequine and a hydroxy metabolite in biological fluids by high-pressure liquid chromatographic, fluorometric, and microbiological methodsL I Harrison, D Schuppan, S R Rohlfing, et al.
British Journal of Cancer|October 25, 2017
Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic reviewA Prawira, S F Oosting, T W Chen, et al.
Gynecologic Oncology|July 14, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 studyD M O'Malley, G M Bariani, P A Cassier, et al.
Oral Oncology|May 29, 2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neckD Day, A Prawira, A Spreafico, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyA R Hansen, C Massard, P A Ott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)A Spreafico, A A Heirali, D V Araujo, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumI Stukalin, J C Wells, J Graham, et al.
Pageof 5